Daewoong’s Nabota enters advanced market with Canadian approval
Daewoong Pharmaceutical’s Nabota has finally opened a new pharmaceutically advanced market.
Daewoong Pharmaceutical(CEO Seung-Ho Jeon) announced its self-developed botulinum toxin product ‘Nabota’ was approved from the Health Canada on the 16th. The Health Canada approved the Nabota’s indication...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
